CoChat

Blood-based biomarkers of antidepressant response to ketamine and esketamine: A systematic review and meta-analysis

Open access

The DOI matches its Crossref record; 134 of the 136 references it cites were found in a registry or an index.

Abstract

(R,S)-ketamine (ketamine) and its enantiomer (S)-ketamine (esketamine) can produce rapid and substantial antidepressant effects. However, individual response to ketamine/esketamine is variable, and there are no well-accepted methods to differentiate persons who are more likely to benefit. Numerous potential peripheral biomarkers have been reported, but their current utility is unclear. We conducted a systematic review/meta-analysis examining the association between baseline levels and longitudinal changes in blood-based biomarkers, and response to ketamine/esketamine. Of the 5611 citations identified, 56 manuscripts were included (N = 2801 participants), and 26 were compatible with meta-analytical calculations. Random-effect models were used, and effect sizes were reported as standardized mean differences (SMD). Our assessments revealed that more than 460 individual biomarkers were examined. Frequently studied groups included neurotrophic factors (n = 15), levels of ketamine and ketamine metabolites (n = 13), and inflammatory markers (n = 12). There were no consistent associations between baseline levels of blood-based biomarkers, and response to ketamine. However, in a longitudinal analysis, ketamine responders had statistically significant increases in brain-derived neurotrophic factor (BDNF) when compared to pre-treatment levels (SMD [95% CI] = 0.26 [0.03, 0.48], p = 0.02), whereas non-responders showed no significant changes in BDNF levels (SMD [95% CI] = 0.05 [-0.19, 0.28], p = 0.70). There was no consistent evidence to support any additional longitudinal biomarkers. Findings were inconclusive for esketamine due to the small number of studies (n = 2). Despite a diverse and substantial literature, there is limited evidence that blood-based biomarkers are associated with response to ketamine, and no current evidence of clinical utility.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41380-022-01652-1

Cites

134 of 134 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 134 references

Research works printed but not linked: 5

  1. FDA-NIH Biomarker Working Group. BEST (Biomarkers, EndpointS, and other Tools) Resource. Silver Spring (MD): Food and Drug Administration (US); Bethesda (MD): National Institutes of Health (US) www.ncbi.nlm.nih.gov/books/NBK326791/ (2016).
  2. Niciu MJ, Luckenbaugh DA, Ionescu DF, Guevara S, Machado-Vieira R, Richards EM, et al. Clinical predictors of ketamine response in treatment-resistant major depression. J Clin Psychiatry. 2014;75:e417. · DOI · Paper page
  3. Covidence systematic review software, Veritas Health Innovation, Melbourne, Australia. Available at www.covidence.org.
  4. Sos P, Klirova M, Novak T, Kohutova B, Horacek J, Palenicek T. Relationship of ketamine’s antidepressant and psychotomimetic effects in unipolar depression. Neuroendocrinol Lett. 2013;34:101–7.
  5. Farmer CA, Gilbert JR, Moaddel R, George J, Adeojo L, Lovett J, et al. Ketamine metabolites, clinical response, and gamma power in a randomized, placebo-controlled, crossover trial for treatment-resistant major depression. Neuropsychopharmacology. 2020;45:1398–404. · DOI · Paper page

Cited by

See all 84

Metadata

Authors
Medeiros, G. C., Gould, T. D., Prueitt, W. L., Nanavati, J., Grunebaum, M. F., Farber, N. B., Singh, B., Selvaraj, S., Machado-Vieira, R., Achtyes, E. D., Parikh, S. V., Frye, M. A., Zarate, C. A., & Goes, F. S.
Affiliations
  • University of Maryland, Baltimore (US)
  • Yale University (US)
  • Johns Hopkins University (US)
  • Columbia University Irving Medical Center (US)
  • Washington University in St. Louis (US)
  • Mayo Clinic (US)
  • The University of Texas Health Science Center at Houston (US)
  • Pine Rest Christian Mental Health Services (US)
  • University of Michigan (US)
  • National Institutes of Health (US)
Corresponding author
Goes, Fernando S.
Venue
Molecular Psychiatry
Published
2022-06-27
Volume
27
Issue
9
Pages
3658-3669
ISSN
  • 1359-4184 (ISSN-L)
  • 1476-5578
OpenAlex
W4283711009
Cited by
75
References
136
Citations by year
2026: 14 · 2025: 31 · 2024: 21 · 2023: 6 · 2022: 3
FWCI
2.19
Type
journal article
Language
en
Open access
Licence
Locations
  • Molecular Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • U.S. Department of Veterans Affairs (I01BX004062, I01 BX003631)
  • National Institutes of Health (5r21mh119441-02)
  • National Institute of Mental Health (R21 MH119441, R01MH107615)
  • National Institute of Allergy and Infectious Diseases (R21AI145211)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
  • Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
Keywords
ketamine, esketamine, antidepressant response, blood-based biomarkers, brain-derived neurotrophic factor, neurotrophic factors, ketamine metabolites, inflammatory markers, depression, rapid-acting antidepressants, treatment response prediction
MeSH terms
Antidepressive Agents, Humans, Ketamine, Biomarkers, Brain-Derived Neurotrophic Factor, Depressive Disorder, Treatment-Resistant

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Blood-based biomarkers of antidepressant response to ketamine and esketamine: A systematic review and meta-analysis. https://app.cochat.ai/papers/10.1038/s41380-022-01652-1
The paper
Medeiros, G. C., Gould, T. D., Prueitt, W. L., Nanavati, J., Grunebaum, M. F., Farber, N. B., Singh, B., Selvaraj, S., Machado-Vieira, R., Achtyes, E. D., Parikh, S. V., Frye, M. A., Zarate, C. A., & Goes, F. S. (2022). Blood-based biomarkers of antidepressant response to ketamine and esketamine: A systematic review and meta-analysis. Molecular Psychiatry. https://doi.org/10.1038/s41380-022-01652-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.